(VIANEWS) – Iamgold Corporation Ordinary Shares (IAG), TG Therapeutics (TGTX), Verisk Analytics (VRSK) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Iamgold Corporation Ordinary Shares (IAG)
69.7% sales growth and 6.57% return on equity
IAMGOLD Corporation, through its subsidiaries, explores, develops, and operates gold mining properties in North America, South America, and West Africa. The company owns interests in the Rosebel mine located in Suriname, South America; the Essakane mine situated in Burkina Faso and Boto gold project located in Senegal, West Africa; and Westwood mine, covers an area of 1,925 hectare and located in Quebec and the Côté gold project, which covers an area of 586 square kilometer located in Ontario, Canada. Its exploration and development projects include the Pitangui project in Brazil; the Karita project located in Guinea; the Diakha-Siribaya project situated in Mali; and the Nelligan and Monster Lake projects located in Quebec, Canada. IAMGOLD Corporation was incorporated in 1990 and is headquartered in Toronto, Canada.
Earnings Per Share
As for profitability, Iamgold Corporation Ordinary Shares has a trailing twelve months EPS of $0.18.
PE Ratio
Iamgold Corporation Ordinary Shares has a trailing twelve months price to earnings ratio of 23.89. Meaning, the purchaser of the share is investing $23.89 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 6.57%.
Moving Average
Iamgold Corporation Ordinary Shares’s value is way above its 50-day moving average of $3.43 and way higher than its 200-day moving average of $2.66.
2. TG Therapeutics (TGTX)
67.5% sales growth and 43.93% return on equity
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York.
Earnings Per Share
As for profitability, TG Therapeutics has a trailing twelve months EPS of $0.3.
PE Ratio
TG Therapeutics has a trailing twelve months price to earnings ratio of 54.93. Meaning, the purchaser of the share is investing $54.93 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 43.93%.
Growth Estimates Quarters
The company’s growth estimates for the ongoing quarter is 85.3% and a drop 101.4% for the next.
Volume
Today’s last reported volume for TG Therapeutics is 3268640 which is 12.84% below its average volume of 3750430.
Yearly Top and Bottom Value
TG Therapeutics’s stock is valued at $16.48 at 16:22 EST, way under its 52-week high of $30.07 and way higher than its 52-week low of $6.46.
3. Verisk Analytics (VRSK)
7.2% sales growth and 431.9% return on equity
Verisk Analytics, Inc. provides data analytics and technology solutions to the insurance markets in the United States and internationally. It offers policy language, prospective loss costs, policy writing and rating rules, and various underwriting solutions for risk selection and segmentation, pricing, and workflow optimization; property- and auto- specific rating and underwriting information solutions that allows clients to understand, quantify, underwrite, mitigate, and avoid potential loss for risks; catastrophe modeling solutions, which enables companies to identify, quantify, and plan for the financial consequences of catastrophes for use by insurers, reinsurers, intermediaries, financial institutions, and governments. The company also provides life insurance solutions for transforming current workflows in life insurance underwriting, claim insights, policy administration, unclaimed property/equity, compliance and fraud detection, and actuarial and portfolio modeling; Marketing Solutions, such as compliant, real-time decisioning, profitability, and risk assessment for inbound consumer interactions; and international underwriting and claims solutions. In addition, it offers claims insurance solutions, which provides analytics in fraud detection, compliance reporting, subrogation liability assessment, litigation, and repair cost estimation and valuation solutions; and casualty solutions, such as compliance, casualty claims decision support, and workflow automation solutions. Further, the company supplies software to the specialty insurance market. The company was founded in 1971 and is headquartered in Jersey City, New Jersey.
Earnings Per Share
As for profitability, Verisk Analytics has a trailing twelve months EPS of $5.23.
PE Ratio
Verisk Analytics has a trailing twelve months price to earnings ratio of 42.55. Meaning, the purchaser of the share is investing $42.55 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 431.9%.
Moving Average
Verisk Analytics’s value is below its 50-day moving average of $234.44 and under its 200-day moving average of $237.88.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 8.6% and 8.6%, respectively.
Revenue Growth
Year-on-year quarterly revenue growth grew by 8%, now sitting on 2.73B for the twelve trailing months.
Yearly Top and Bottom Value
Verisk Analytics’s stock is valued at $222.53 at 16:22 EST, way under its 52-week high of $254.14 and higher than its 52-week low of $215.32.
4. Expedia Group (EXPE)
6.9% sales growth and 25.51% return on equity
Expedia Group, Inc. operates as an online travel company in the United States and internationally. The company operates through B2C, B2B, and trivago segments. Its B2C segment includes Brand Expedia, a full-service online travel brand offers various travel products and services; Hotels.com for lodging accommodations; Vrbo, an online marketplace for the alternative accommodations; Orbitz, Travelocity, Wotif Group, ebookers, CheapTickets, Hotwire.com and CarRentals.com. The company's B2B segment provides various travel and non-travel companies including airlines, offline travel agents, online retailers, corporate travel management, and financial institutions who leverage its travel technology and tap into its diverse supply to augment their offerings and market Expedia Group rates and availabilities to its travelers. Its trivago segment, a hotel metasearch website, which send referrals to online travel companies and travel service providers from hotel metasearch websites. In addition, the company provides brand advertising through online and offline channels, loyalty programs, mobile apps, and search engine marketing, as well as metasearch, social media, direct and personalized traveler communications on its websites, and through direct e-mail communication with its travelers. The company was formerly known as Expedia, Inc. and changed its name to Expedia Group, Inc. in March 2018. Expedia Group, Inc. was founded in 1996 and is headquartered in Seattle, Washington.
Earnings Per Share
As for profitability, Expedia Group has a trailing twelve months EPS of $5.32.
PE Ratio
Expedia Group has a trailing twelve months price to earnings ratio of 24.52. Meaning, the purchaser of the share is investing $24.52 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 25.51%.
